Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing since 12/18/2024, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Monopar Therapeutics
13G/A
Amendment 1
MNPR · 61023L207
|
4.7% |
8/12/2026
Event 6/30/2026
|
|||
| Saturn V Capital Management LP | 4.7% | ||||
| Xiaoying Tian | 4.7% | ||||
|
Monopar Therapeutics Inc.
13G
MNPR · 61023L207
|
5.2% |
5/15/2026
Event 1/5/2026
|
|||
| Saturn V Capital Management LP | 5.2% | ||||
| Xiaoying Tian | 5.2% | ||||
|
Immix Biopharma, Inc.
13G
IMMX · 45258H106
|
7.0% |
2/17/2026
Event 12/26/2025
|
|||
| Saturn V Capital Management LP | 7.0% | ||||
| Xiaoying Tian | 7.0% | ||||
|
X4 Pharmaceuticals, Inc.
13G
XFOR · 98420X202
|
7.4% |
2/17/2026
Event 10/24/2025
|
|||
| Saturn V Capital Management LP | 7.4% | ||||
| Xiaoying Tian | 7.4% | ||||